BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - 2Astronaut on ISS captures spectacular orbital video of zodiacal light, auroras and the Pleiades
- 3Violence 'never part' of break-in plan, court told
- 4At least 490 protesters killed in Iran, activists say
- 5The Most Compelling Innovation Advancements Somewhat recently
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- 'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- Russia accidentally destroys its only way of sending astronauts to space
- Major Scottish gangland figure Steven Lyons arrested in Bali
- First part of major new German-Danish tunnel cleared for lowering
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Gaza Strip sees flooding after heavy rainfall
- Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
